High-grade/large B-cell lymphoma with 11q aberration: A distinct molecularly defined entity in contemporary pathobiological classifications

This is the authors' abstract. We don't add key points for this paper.

Purpose High-grade/large B-cell lymphoma with 11q aberration (HGBCL-11q) is an aggressive mature B-cell lymphoma that mimics Burkitt lymphoma (BL) but lacks MYC -rearrangements. Correct diagnosis is essential to avoid misclassification and to support (future) risk-adapted management. Methods We reviewed recent classification updates, pivotal clinicopathologic reports, and genomic studies addressing HGBCL-11q. Accordingly, we summarized diagnostic criteria including histomorphology, immunophenotype and genomics, and collate reported clinical characteristics and treatment outcomes. Results HGBCL-11q is characterized by a chromosome 11q copy-number profile with a proximal gain/amplification at 11q23.2–q23.3 and a distal loss at 11q24.1–qter. Tumours typically show a germinal centre B-cell immunophenotype and BL-like histomorphology, yet genome-wide profiling supports assignment within the large B-cell lymphoma (LBCL) spectrum rather than true BL. HGBCL-11q predominantly affects children and adolescents and often presents with localized nodal disease in the head-and-neck region. In the largest multinational cohort of 72 pediatric patients, 3-year event-free and overall survival were 94% and 96%, respectively, with inferior outcomes mainly confined to patients with inborn and acquired errors of immunity or cancer predisposition syndromes. Conclusion HGBCL-11q is a genetically defined non-Hodgkin lymphoma with an excellent lymphoma-related prognosis under pediatric mature B-cell lymphoma–type regimens. Standardized testing for 11q aberration in cases of diffuse LBCL, HGBCL or BL morphology lacking MYC -rearrangements improves classification consistency and may enable chemoimmunotherapy de-escalation trials. Systematic evaluation for immunodeficiency and cancer predisposition syndromes is recommended to identify patients at risk and guide adapted therapy, supportive care and follow-up.